although the acceptance of screening was controversial.
patients from the United Kingdom received infusions
There was concern that transmission of hepatitis C was suspected acute hepatitis C infection were reported after States and in Sweden were associated with different contaminated batches of the product, and because several batches were implicated, identification and subsequent
I
follow-up was more difficult. 17 In this study, we report ntravenous (IV) immunoglobulin (Ig) is an established therapy for immune deficiency. It is used in the management of primary 1 and secondary immune deficiency 2, 3 Abbreviations used in this paper: CVID, common variable immunoand as an immunomodulatory agent in many autoimdeficiency; RT-PCR, reverse-transcription polymerase chain reaction.
mune diseases. 4 As IV Ig therapy developed through NS-5 sequence recovered from the implicated batch of Gamthe initial follow-up of the exposed patients in the United magard.
Kingdom.
Results

Patients and Methods
Patient Details
In late February 1994, abnormal liver function was Forty-six questionnaires were returned from 48 detected in several patients in the United Kingdom who were identified patients who received Gammagard at the 19 receiving Gammagard. All of these patients had been treated with one particular batch (93F21AB11B) within the preceding local centers, regardless of the batch numbers within the 7 weeks (from December 20, 1993 , to February 18, 1994 93F21AB11B was 9.88 (Greenland-Robbins 95% congene, which was amplified, sequenced, and analyzed as prefidence limits, 1.50 õ relative risk õ 64.92; P Å viously described. 18 Phylogenetic relationships were investi-0.0001) with an odds ratio of 51.33 (Cornfield 95% gated between nucleotide sequences amplified from patients confidence limits, 4.84 õ odds ratio õ 1315). sequence amplified from batch 93F21AB11B (Figure 1 ).
Clinical features Exposed Not exposed Total
This is consistent with transmission from this batch and 1 Ig subclass deficiency, and 2 myelomas).
Clinical Features
Nine of the 34 exposed patients (27%) developed for HCV using PCR; 4 patients were tested on at least three occasions up to 4 months after exposure, and the jaundice (bilirubin level, ú50 IU/L), and 27 of the 34 (79.4%) had abnormal liver transferase levels (aspartate other 2 have been tested twice. Two of the HCV RNAnegative patients had abnormal liver function test results aminotransferase or alanine aminotransferase) within 4 months after the first exposure to the contaminated and have seroconverted for anti-HCV. The first patient had myeloma and recommenced IV Ig therapy with anbatch. In all patients with abnormal liver transaminase levels, abnormal values were found on more than one other anti-HCV-screened product. The other had Ig deficiency and Crohn's disease and developed abnormal liver occasion. The mean time from individual exposure to batch 93F21AB11B to the first documented abnormal function after exposure (documented by his primary care physician); however, when finally tested for HCV markliver transaminase level was 44.59 days (range, 4-119 days; n Å 22; with 60% of values abnormal on the ers (101 days after exposure), he had seroconverted for anti-HCV antibody but RNA was negative. In HCVfirst available testing after exposure). Eighteen of the 34 patients who received the contaminated batch (52.9%) positive cases by PCR, 26 of 28 patients (92.3%) tested positive on the first test after exposure. The mean length developed the following symptoms: malaise in 13, dark urine in 3, pruritus in 2, and food intolerance or nausea of time from exposure to batch 93F21AB11B to the first positive HCV PCR test result was 37.5 days (range, 7-in 4. Histological analysis of the liver was performed on 3 patients: 2 had acute inflammation of the liver typical 71 days; n Å 22; 1 SD Å 19.3). Nine of the 12 patients who underwent Gammagard therapy but who did not of HCV hepatitis. The third was a patient with chronic lymphocytic leukemia who died suddenly of unrelated receive the implicated batch (93F21AB11B) have all tested negative for HCV PCR on at least two occasions.
causes; postmortem examination showed marked lymphocytic infiltration of the liver with lymphoid folliOf the 3 remaining patients, 1 patient was positive by PCR previously and had chronic hepatitis C infection cle formation. Immunohistochemical staining has shown the cells to be predominately of T-cell origin (suggesting after transmission by previous IV Ig product (not Gammagard); 1 patient has been tested only once (negative); HCV rather than chronic lymphocytic leukemia as the cause of the changes). Only 1 of the 12 patients not and data were not available for the third patient. In 21 of the 34 exposed patients (61.8%), sera were available exposed to the implicated batch (93F21AB11B) had any documented change in liver function test results; this before exposure (in 15 of 21 patients [71.4%] sera were available from the month immediately before their expochange was transient after a chest infection treated with broad-spectrum antibiotics. sure) and they tested for RT-PCR. Only 1 of these patient was HCV RNA-positive before exposure. He was a paThe 4 patients exposed to the batch but who had no findings of HCV viremia or anti-HCV seroconversion tient with common variable immunodeficiency (CVID) and autoimmune hemolytic anemia who had received did not seem to be significantly different in age, sex, indication for IV Ig (two CVIDs and two Ig subclass other blood products in the past. Genotyping of 20 isolates from 14 patients have all shown genotype 1a.
deficiencies), or dose of the implicated batch. 19 Each batch of Gammagard is produced from (93F21AB11B) of Gammagard, 30 developed HCV infection. Twenty-eight were found to be HCV positive a plasma pool (approximately 12,000 L) made from approximately 15,000 individual donations from several by PCR, and 2 patients were anti-HCV positive with abnormal liver function tests. Sequence analysis has thousand donors. The plasma pool then undergoes cryoprecipitation and alcohol precipitation to produce several shown almost identical virus isolates from the implicated batch as well as all 20 isolates tested from the recipients. protein fractions; the g-globulin-containing fraction is further purified by chromatography. Although the alcoDiscussion hol precipitation steps have been shown to denature reWe have shown that the use of an IV Ig product troviruses, the ability to remove HCV is unproven. 20 (Gammagard) made from blood screened for anti-HCV HCV RNA could still be detected by nested PCR in the antibody was associated with the transmission of acute g-globulin fraction but at a greatly reduced titer comhepatitis C from one contaminated batch. No infection pared with that of the starting plasma pool, so that infecwas found in patients treated with 16 different batches tivity was thought to be unlikely. 15 In addition, IV Ig of the same product in the United Kingdom during the made from infectious plasma using various methods, in-14 months before withdrawal. Analysis of virus isolates cluding that used to produce Gammagard, had been from the infected patients has shown the same subtype shown not to transmit HCV to chimpanzees in limited of the virus, and nucleotide sequence analysis of the NS5 animal tests. 21 Whether this outbreak is related to HCV region of the viral genome shows virtually no variation screening or proves to be restricted to the manufacturing between any of the isolates. An identical sequence has process (now modified by the addition of solvent or deteralso been amplified from the implicated batch. Such gent inactivation) is unknown. findings are consistent with infection from a single donor.
Because of the concern for potential HCV transmisFor breakthrough of HCV infection to have occurred, sion, improvements in the production of IV Ig have been there must have been both failure of anti-HCV screening introduced, such as the addition of a solvent detergent to detect donor infection and lack of complete removal step for the inactivation of HCV because this virus is of infectious HCV by the production method. Anti-HCV sensitive to organic solvents. The transmission of viruses through the use of blood markers such as abnormal transaminase values may furand blood products has been a major medical problem, ther identify HCV-positive donors who remain negative perhaps most tragically illustrated with the inadvertent on anti-HCV tests. However, HCV infection is often human immunodeficiency virus infection of hemophilifound with persistently normal liver function despite acs. However, the problem has not been restricted to active liver disease. 22 One possible option would be introhuman immunodeficiency virus, as clearly shown by the ducing HCV RNA testing of the finished IV Ig product, current outbreak of hepatitis C that accompanied the use although interpretation of positive results remains uncerof screened IV Ig (Gammagard). This emphasizes the tain with regard to infectivity.
importance of regarding Ig preparations with the same care that is afforded to other blood products. Careful In immunocompetent individuals, hepatitis C usually documentation of batch numbers and regular biochemicauses chronic infection that may progress to cirrhosis cal monitoring is recommended for all IV Ig recipients. and hepatocellular carcinoma. [23] [24] [25] [26] There have been several previous outbreaks of non-A, non-B hepatitis associ-cant liver disease (Table 2) relapse rates, and significant side effects. 28 The use of HCV and is the subject of further study in the follow- group of antibody-deficient patients is somewhat surprising. 
